Biocon inks patent litigation settlement pact with Celgene

The company along with its subsidiaries has entered into a confidential settlement agreement with Celgene Corporation, a wholly-owned subsidiary of Bristol Myers Squibb, relating to patents for Revlimid (lenalidomide), the Bengaluru-based company said in a regulatory filing.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news